Abstract
Introduction

Transplantation of haematopoietic stem cells (HSCs) is considered to be one of successful alternatives to treat malignant and nonmalignant haematopoietic disease
, and a new therapy for non-haematologic diseases, including autoimmune diseases, multiple organ dysfunction and allogeneic transplantation rejection [3] [4] [5] [6] [7] . [8, 9] , have faster availability of banked cryopreserved UCB units [10, 11] , and process the tolerance of one to two human leucocyte antigen (HLA) locus mismatch [12] .
HSCs can be recovered from bone marrow (BM), peripheral blood (PB) and umbilical cord blood (UCB). HSCs from UCB have been suggested to be the major resource for clinical applications of HSC transplantation. UCB-HSC transplantation has a number of advantages, e.g. to reduce the incidence of acute graft-versus-host disease
However, it remains largely unknown that how can donor HSCs, particularly from UCB resource, engraft successfully in vivo in a host with intact innate immunity. Natural killer (NK) cells play a fundamental role in the innate immune response through their ability to secrete cytokines and kill target cells without prior sensitization. The cytotoxic effect of NK cells is executed via natural cytotoxicity receptors (NCRs) expressed on NK cells and HLA-G expressed on target cells. NCRs is a main group of the killer cell activatory receptors, include NKp30, NKp44 and NKp46, through which NK cell activationincreased intracellular Ca
2ϩ flux may trigger cytotoxicity and lymphokine release [13] [14] [15] [16] [22] . 
Cytotoxic assays
The cytolytic activity of PB-NK cells and NK-92 cells against the HSCs was assessed in 4-hr lactate dehydrogenase (LDH) release assay using CytoTox
Colony forming cell (CFC) assay
05). The similar inhibitory effects of blocking the expressions of NKp30L, NKp44L and NKp46L were noted on PB-HSCs, BM-HSCs and UCB-HSCs (Fig. 3B). All the results indicate that, lower expression of NCR ligands protects HSCs against NK cytolysis. However, it is just one possible mechanism in the protection of UCB-HSCs against NK cytolysis.
High levels of HLA-G protected UCB-HSCs against NK cytolysis
To further illuminate why UCB-HSCs have more potent ability than the other two HSCs to escape from NK cell mediated cytolysis, the expressions of immune tolerance molecule HLA-G were tested. As shown in Figure 4A, UCB-HSCs expressed high level of HLA-G (57.6%), whereas PB-HSCs and BM-HSCs expressed scarcely HLA-G (0.2% and 0.1%, respectively). When neutralized with anti-HLA-G monoclonal Ab, NK cell mediated cytolysis rate of UCB-HSCs significantly increased from 7.530 Ϯ 0.429% to 25.467 Ϯ 0.679% (Fig. 4B, P Ͻ 0.05), indicating that HLA-G contribute to the immune resistance of UCB-HSCs to the cytolysis of NK cells. Taken together, all the results demonstrate that, low-level cross-talking of NCRs with their ligands and high-level expression of HLA-G protect UCB-HSCs from NK-mediated cytolysis.
Discussion
Transplanted stem cells escape from the attacking by the host immune system as the first step of transplantation tolerance. Its mechanism remains elusive, although mixed haematopoietic chimerism was suggested to lead to tolerance [4] . The results [24, 25] , probably through different transmembrane-anchored polypeptides associated with immune tyrosine-based activating motifs bearing adapter molecule DAP12 [26] [29] . In patients with heart transplantation, HLA-G was found to be correlated with better graft acceptance [20] . 
Fig. 1 NK cell cytolysis of peripheral blood NK cell (A) and NK-92 (B) in peripheral blood (PB), bone marrow (BM) and umbilical cord blood (UCB) haematopoietic stem cells (HSCs) by the 4-hr LDH release assay at five different effector cell:target cell (E:T) ratios. Peripheral blood monocytes depleting PB-HSCs are used as control cells. Inhibition of peripheral blood NK cell against the proliferation of HSCs (C) was measured by the Colony Forming Cell Assay after co-culture with effector cells for 4 hrs. E:T
